{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:53:13Z","timestamp":1760205193900,"version":"3.40.4"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Treatment with monoclonal antibodies has been shown to significantly reduce the risk of hospitalization and disease progression among high-risk patients with coronavirus disease 2019 (COVID-19). Pregnant individuals were excluded from the original trials. In this single-center retrospective cohort study, we evaluated whether monoclonal antibody treatment in pregnant individuals is associated with decreased risk of hospitalization. Outcomes of patients who received the treatment were compared with those who were eligible but did not receive the treatment. Analyses were stratified by vaccination status. Unvaccinated pregnant patients with mild or moderate COVID-19 who received outpatient monoclonal antibodies were less likely to be admitted to the hospital (4.2% vs 15.7%, odds ratio 0.24, 95% CI 0.07\u20130.74), whereas among vaccinated patients, the treatment was not associated with a lower rate of hospitalization (2.3% vs 0%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.99).<\/jats:p>","DOI":"10.1097\/aog.0000000000004826","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:01:36Z","timestamp":1655157696000},"page":"74-76","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Outpatient Use of Monoclonal Antibodies in Pregnant Individuals With Mild or Moderate Coronavirus Disease 2019 (COVID-19)"],"prefix":"10.1097","volume":"140","author":[{"given":"Joe","family":"Eid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Malvestutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Landon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maged M.","family":"Costantine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara M.","family":"Rood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R4-20250423","first-page":"937","article-title":"Monoclonal antibodies casirivimab and imdevimab in pregnancy for coronavirus disease 2019 (COVID-19)","volume":"138","author":"Mayer","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajog.2021.08.025","article-title":"Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report","volume":"225","author":"Hirshberg","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20250423","first-page":"616","article-title":"Anti-spike monoclonal antibody therapy in pregnant women with mild-to-moderate coronavirus disease 2019 (COVID-19)","volume":"139","author":"Thilagar","year":"2022","journal-title":"Obstet Gynecol"},{"key":"R7-20250423","first-page":"368","article-title":"Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: a case series","volume":"139","author":"Richley","year":"2022","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:00:17Z","timestamp":1745431217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004826","relation":{},"ISSN":["0029-7844"],"issn-type":[{"type":"print","value":"0029-7844"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"2022-02-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}